{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T13:15:50Z","timestamp":1759497350895,"version":"build-2065373602"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.yrtph.2022.105182","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T21:47:13Z","timestamp":1651182433000},"page":"105182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Results from two-year rodent oral carcinogenicity studies of cizolirtine, a substance-P and calcitonin gene-related peptide release modulator"],"prefix":"10.1016","volume":"132","author":[{"given":"Antonio","family":"Guzm\u00e1n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Araceli","family":"Tortajada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana-Paz","family":"Mar\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Vila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregorio","family":"Encina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yrtph.2022.105182_bib1","first-page":"211","article-title":"Pharmacology of cizolirtine: a new analgesic agent. Methods Find","volume":"22","author":"Alvarez","year":"2000","journal-title":"Exp. Clin. Pharmacol."},{"key":"10.1016\/j.yrtph.2022.105182_bib2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.tox.2010.10.006","article-title":"Strategies for the early detection of drug-induced hepatic steatosis in preclinical drug safety evaluation studies","volume":"279","author":"Amacher","year":"2011","journal-title":"Toxicology"},{"key":"10.1016\/j.yrtph.2022.105182_bib3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/0023677213476278","article-title":"Group housing of male CD1 mice: reflections from toxicity studies","volume":"47","author":"Annas","year":"2013","journal-title":"Lab. Anim."},{"key":"10.1016\/j.yrtph.2022.105182_bib4","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3109\/10408448509037459","article-title":"Regeneration and the mechanism of epidermal tumor promotion","volume":"14","author":"Argyris","year":"1985","journal-title":"CRC Crit. Rev. Toxicol."},{"key":"10.1016\/j.yrtph.2022.105182_bib5","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-642-16499-6_19","article-title":"Neuropeptides in lower urinary tract function","author":"Arms","year":"2011","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.yrtph.2022.105182_bib6","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.neuropharm.2006.08.017","article-title":"Evidence for adenosine- and serotonin-mediated antihyperalgesic effects of cizolirtine in rats suffering from diabetic neuropathy","volume":"52","author":"Aubel","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.yrtph.2022.105182_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.pain.2004.03.001","article-title":"Antihyperalgesic effects of cizolirtine in diabetic rats: behavioral and biochemical studies","volume":"110","author":"Aubel","year":"2004","journal-title":"Pain"},{"key":"10.1016\/j.yrtph.2022.105182_bib8","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S0028-3908(00)00186-6","article-title":"The novel analgesic, cizolirtine, inhibits the spinal release of substance P and CGRP in rats","volume":"40","author":"Ballet","year":"2001","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.yrtph.2022.105182_bib9","first-page":"134","article-title":"Significance of hepatic preneoplasia in risk identification and early detection of neoplasia","volume":"31","author":"Bannasch","year":"2003","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.yrtph.2022.105182_bib10","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2307\/2983644","article-title":"Some examples of statistical methods of research in agriculture and applied biology. Suppl","volume":"4","author":"Bartlett","year":"1937","journal-title":"J. Roy. Stat. Soc."},{"key":"10.1016\/j.yrtph.2022.105182_bib11","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/bjc.1978.62","article-title":"Long-term effects of phenobarbitone-Na on male Fischer rats","volume":"37","author":"Butler","year":"1978","journal-title":"Br. J. Cancer"},{"year":"1957","series-title":"Experimental Designs","author":"Cochran","key":"10.1016\/j.yrtph.2022.105182_bib12"},{"key":"10.1016\/j.yrtph.2022.105182_bib13","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/JCP.0b013e31823f8770","article-title":"The psychopharmacology of aggressive behavior: a translational approach: part 1: neurobiology","volume":"32","author":"Comai","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.yrtph.2022.105182_bib14","doi-asserted-by":"crossref","first-page":"482","DOI":"10.2307\/2528490","article-title":"New tables for multiple comparisons with a control","volume":"20","author":"Dunnett","year":"1964","journal-title":"Biometrics"},{"key":"10.1016\/j.yrtph.2022.105182_bib15","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1080\/01621459.1955.10501294","article-title":"A multiple comparison procedure for comparing several treatments with a control","volume":"50","author":"Dunnett","year":"1955","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.yrtph.2022.105182_bib16","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3109\/10408444.2013.835786","article-title":"Mode of action and human relevance analysis for nuclear receptor-mediated liver toxicity: a case study with phenobarbital as a model constitutive androstane receptor (CAR) activator","volume":"44","author":"Elcombe","year":"2014","journal-title":"Crit. Rev. Toxicol."},{"key":"10.1016\/j.yrtph.2022.105182_bib17","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/009286159803200212","article-title":"Biostatistical methodology in carcinogenicity studies","volume":"32","author":"Fairweather","year":"1998","journal-title":"Drug Inf. J."},{"key":"10.1016\/j.yrtph.2022.105182_bib18","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1358\/dof.2002.027.08.692100","article-title":"Cizolirtine citrate","volume":"27","author":"Farre","year":"2002","journal-title":"Drugs Future"},{"year":"2004","series-title":"Estorra (Eszopiclone) - New Drug Application (NDA) Drug Approval Package","key":"10.1016\/j.yrtph.2022.105182_bib19"},{"key":"10.1016\/j.yrtph.2022.105182_bib20","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1055\/a-1286-5358","article-title":"Assessment of the genotoxic potential of cizolirtine a substance-P and calcitonin gene-related peptide release modulator","volume":"71","author":"Fern\u00e1ndez de Henestrosa","year":"2021","journal-title":"Drug Res."},{"volume":"96","year":"1973","author":"Fisher","key":"10.1016\/j.yrtph.2022.105182_bib21"},{"key":"10.1016\/j.yrtph.2022.105182_bib22","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.yrtph.2011.04.001","article-title":"Evaluation of carcinogenicity studies of medicinal products for human use authorised via the European centralised procedure (1995-2009)","volume":"60","author":"Friedrich","year":"2011","journal-title":"Regul. Toxicol. Pharmacol. RTP"},{"key":"10.1016\/j.yrtph.2022.105182_bib23","series-title":"Guides for Toxicologic Pathology","first-page":"1","article-title":"Proliferative and selected other lesions in the liver of the rat","author":"Goodman","year":"1994"},{"key":"10.1016\/j.yrtph.2022.105182_bib24","series-title":"Histopathology of Preclinical Toxicity Studies","first-page":"457","article-title":"Chapter 9 - liver and pancreas","author":"Greaves","year":"2007"},{"key":"10.1016\/j.yrtph.2022.105182_bib25","doi-asserted-by":"crossref","first-page":"104916","DOI":"10.1016\/j.yrtph.2021.104916","article-title":"Twenty six-week repeat dose oral rat toxicity study of cizolirtine, a substance-P and calcitonin gene-related peptide release modulator","volume":"122","author":"Guzm\u00e1n","year":"2021","journal-title":"Regul. Toxicol. Pharmacol. RTP"},{"key":"10.1016\/j.yrtph.2022.105182_bib26","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0149-7634(97)00023-7","article-title":"Catecholaminergic involvement in the control of aggression: hormones, the peripheral sympathetic, and central noradrenergic systems","volume":"22","author":"Haller","year":"1998","journal-title":"Neurosci. Biobehav. Rev."},{"year":"1996","series-title":"The Need for Carcinogenicity Studies of Pharmaceuticals","key":"10.1016\/j.yrtph.2022.105182_bib27"},{"year":"1997","series-title":"Carcinogenicity: Testing for Carcinogenicity of Pharmaceuticals","key":"10.1016\/j.yrtph.2022.105182_bib28"},{"year":"1991","series-title":"Infectious Diseases of Mice and Rats","key":"10.1016\/j.yrtph.2022.105182_bib29"},{"key":"10.1016\/j.yrtph.2022.105182_bib30","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.yrtph.2022.105182_bib31","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0304-3959(02)00497-9","article-title":"Effects of the novel analgesic, cizolirtine, in a rat model of neuropathic pain","volume":"104","author":"Kayser","year":"2003","journal-title":"Pain"},{"key":"10.1016\/j.yrtph.2022.105182_bib32","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/0192623315623265","article-title":"Scientific and regulatory policy committee: recommended (\u201cBest\u201d) practices for determining, communicating, and using adverse effect data from nonclinical studies","volume":"44","author":"Kerlin","year":"2016","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.yrtph.2022.105182_bib33","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1177\/019262339802600305","article-title":"Appropriate parameters to be tested in rodent oncogenicity studies","volume":"26","author":"Long","year":"1998","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.yrtph.2022.105182_bib34","first-page":"163","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration","volume":"50","author":"Mantel","year":"1966","journal-title":"Cancer Chemother. Rep."},{"key":"10.1016\/j.yrtph.2022.105182_bib35","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.eururo.2008.04.027","article-title":"Cizolirtine citrate, an effective treatment for symptomatic patients with urinary incontinence secondary to overactive bladder: a pilot dose-finding study","volume":"56","author":"Mart\u00ednez-Garc\u00eda","year":"2009","journal-title":"Eur. Urol."},{"key":"10.1016\/j.yrtph.2022.105182_bib36","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1185\/0300799009117014","article-title":"Dose response and safety of cizolirtine citrate (E-4018) in patients with pain following extraction of third molars","volume":"16","author":"Matthew","year":"2000","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.yrtph.2022.105182_bib37","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/004982598239399","article-title":"Enzyme-inducing effects of bicalutamide in mouse, rat and dog","volume":"28","author":"McKillop","year":"1998","journal-title":"Xenobiotica"},{"key":"10.1016\/j.yrtph.2022.105182_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/0014-2999(94)90436-7","article-title":"Antagonism of substance P and related peptides by RP 67580 and CP-96,345, at tachykinin NK1 receptor sites, in the rat urinary bladder","volume":"251","author":"Montier","year":"1994","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.yrtph.2022.105182_bib39","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S0149-2918(04)90178-6","article-title":"Comparison of cizolirtine citrate and metamizol sodium in the treatment of adult acute renal colic: a randomized, double-blind, clinical pilot study","volume":"26","author":"Pavlik","year":"2004","journal-title":"Clin. Therapeut."},{"key":"10.1016\/j.yrtph.2022.105182_bib40","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/bjc.1974.45","article-title":"Guidelines on the analysis of tumour rates and death rates in experimental animals","volume":"29","author":"Peto","year":"1974","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.yrtph.2022.105182_bib41","first-page":"311","article-title":"Guidelines for simple, sensitive significance tests for carcinogenic effects in long-term animal experiments","author":"Peto","year":"1980","journal-title":"IARC Monogr. Eval. Carcinog. Risk Chem. Humans \u2013 Suppl."},{"key":"10.1016\/j.yrtph.2022.105182_bib42","doi-asserted-by":"crossref","first-page":"560","DOI":"10.2307\/2527654","article-title":"A multiple comparison rank sum test: treatments versus control","volume":"15","author":"Steel","year":"1959","journal-title":"Biometrics"},{"year":"2005","series-title":"Evaluation of the Effects of the Administration of Cizolirtine and Other Seven Molecules on Urodynamic Function in Rats","author":"S\u00e1enz de Tejada","key":"10.1016\/j.yrtph.2022.105182_bib43"},{"key":"10.1016\/j.yrtph.2022.105182_bib44","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1093\/carcin\/10.11.2107","article-title":"Transient induction of single GST-P positive hepatocytes by DEN","volume":"10","author":"Satoh","year":"1989","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.yrtph.2022.105182_bib45","series-title":"Mechanism of Toxic Action on Some Target Organs","first-page":"181","article-title":"Liver tumors and steroid hormones in rats and mice","author":"Schuppler","year":"1979"},{"key":"10.1016\/j.yrtph.2022.105182_bib46","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1185\/0300799019117012","article-title":"Cizolirtine citrate (E-4018) in the treatment of chronic neuropathic pain","volume":"17","author":"Shembalkar","year":"2001","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.yrtph.2022.105182_bib47","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2307\/2529789","article-title":"A non-parametric equivalent of Williams' test for contrasting increasing dose levels of a treatment","volume":"33","author":"Shirley","year":"1977","journal-title":"Biometrics"},{"key":"10.1016\/j.yrtph.2022.105182_bib48","article-title":"Distribution and colocalization of calcitonin gene-related peptide, tachykinins, and vasoactive intestinal peptide in normal and idiopathic unstable human urinary bladder","volume":"77","author":"Smet","year":"1997","journal-title":"Lab. Investig. J. Tech. Methods Pathol."},{"key":"10.1016\/j.yrtph.2022.105182_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2016.00492","article-title":"Monoaminergic mechanisms in epilepsy may offer innovative therapeutic opportunity for monoaminergic multi-target drugs","volume":"10","author":"Svob Strac","year":"2016","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.yrtph.2022.105182_bib50","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2307\/2556164","article-title":"The comparison of several dose levels with a zero dose control","volume":"28","author":"Williams","year":"1972","journal-title":"Biometrics"},{"key":"10.1016\/j.yrtph.2022.105182_bib51","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2307\/2528930","article-title":"A test for differences between treatment means when several dose levels are compared with a zero dose control","volume":"27","author":"Williams","year":"1971","journal-title":"Biometrics"},{"key":"10.1016\/j.yrtph.2022.105182_bib52","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/10408444.2021.1939654","article-title":"Critical evaluation of the human relevance of the mode of action for rodent liver tumor formation by activators of the constitutive androstane receptor (CAR)","volume":"51","author":"Yamada","year":"2021","journal-title":"Crit. Rev. Toxicol."},{"key":"10.1016\/j.yrtph.2022.105182_bib53","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1177\/0192623310396512","article-title":"Best practices for clinical pathology testing in carcinogenicity studies","volume":"39","author":"Young","year":"2011","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.yrtph.2022.105182_bib54","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.eururo.2009.04.045","article-title":"Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study","volume":"57","author":"Z\u00e1t\u2019ura","year":"2010","journal-title":"Eur. Urol."}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230022000691?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230022000691?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:33:21Z","timestamp":1759494801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230022000691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":54,"alternative-id":["S0273230022000691"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2022.105182","relation":{},"ISSN":["0273-2300"],"issn-type":[{"type":"print","value":"0273-2300"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Results from two-year rodent oral carcinogenicity studies of cizolirtine, a substance-P and calcitonin gene-related peptide release modulator","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2022.105182","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"105182"}}